AI-based intra-tumor heterogeneity score of Ki67 expression as a prognostic marker for early-stage ER+/HER2- breast cancer.

"Conflict of interest statement: SG, DS and NR are co‐founders of Histofy Ltd. FM, SG, DS and NR are shareholders in Histofy Ltd. FM and NR report research funding from GlaxoSmithKline. NR is also in receipt of research funding from AstraZeneca. The other authors declare no conflicts of interest. All authors are funded by the PathLAKE digital pathology consortium, which is funded from the Data to Early Diagnosis and Precision Medicine strand of the government's Industrial Strategy Challenge Fund, managed and delivered by UK Research and Innovation (UKRI)."

"This paper was supported by the PathLAKE Centre of Excellence for digital pathology and artificial intelligence which is funded from the Data to Early Diagnosis and Precision Medicine strand of HM Government's Industrial Strategy Challenge Fund, managed and delivered by Innovate UK on behalf of UK Research and Innovation (UKRI). Views expressed are those of the authors and not necessarily those of the PathLAKE Consortium members, the NHS, Innovate UK or UKRI. Grant ref: File Ref 104689/application number 18181. Conflict of interest statement: SG, DS and NR are co‐founders of Histofy Ltd. FM, SG, DS and NR are shareholders in Histofy Ltd. FM and NR report research funding from GlaxoSmithKline. NR is also in receipt of research funding from AstraZeneca. The other authors declare no conflicts of interest. All authors are funded by the PathLAKE digital pathology consortium, which is funded from the Data to Early Diagnosis and Precision Medicine strand of the government's Industrial Strategy Challenge Fund, managed and delivered by UK Research and Innovation (UKRI)."